{"entity":{"id":"idea-prev-therapeutic-hpv-vaccine-cin","kind":"idea","name":"A therapeutic vaccine to clear cervical precancer without surgery","aka":[],"tldr":"Precancer is treated by cutting away part of the cervix, which raises pregnancy risks. A vaccine that makes the immune system clear the infected cells would avoid surgery.","summary":"Cervical precancer is treated by cutting away part of the cervix, which raises pregnancy risks, so this idea develops next-generation therapeutic vaccines, mRNA or E6/E7-targeted, that make the immune system clear CIN2/3 lesions, aimed first at women planning pregnancy. HPV oncoproteins are foreign antigens present in every lesion cell, and DNA vaccines such as VGX-3100 have already shown partial efficacy. Endpoints would be histological regression and HPV clearance at six months, allowing surgery to be avoided. The test is a phase 2b RCT of 400 women with a regression endpoint. At early-clinical maturity it addresses the bottlenecks Prevention we already have is not deployed and Overdiagnosis and false alarms, and relates to Cancer interception vaccines for high-risk carriers.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018)","url":"https://doi.org/10.3322/caac.21440"}],"tags":[],"related":["idea-interception-vaccines"],"cancers":["cervical"],"sections":["prevention","immunotherapy"],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-prevention-adoption","b-overdiagnosis"],"keyPapers":["paper-islami-ca-cancer-j-clin"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A therapeutic HPV vaccine achieves at least 50% histological regression with viral clearance at six months in CIN2/3, allowing surgery to be avoided in half of treated women.","rationale":"HPV oncoproteins are foreign antigens present in every lesion cell, and partial efficacy is already proven.","test":"Run a phase 2b RCT of 400 women with a regression endpoint.","maturity":"early-clinical","actor":"industry","cost":"medium","horizonYears":5},"route":"/ideas/idea-prev-therapeutic-hpv-vaccine-cin/","neighbours":{"idea":[{"id":"idea-interception-vaccines","kind":"idea","name":"Cancer interception vaccines for high-risk carriers","route":"/ideas/idea-interception-vaccines/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"}],"bottleneck":[{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/"}],"paper":[{"id":"paper-islami-ca-cancer-j-clin","kind":"paper","name":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","route":"/key-papers/paper-islami-ca-cancer-j-clin/"}]}}